Evidence map›Paper›PMID 40535575›Full record

ArticleCancer management and research2025

Integrating Machine Learning Algorithms to Construct a Triaptosis-Related Prognostic Model in Melanoma.

Jiaheng Xie, Min Zhang, Min Qi

Abstract read
In one paragraph

Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jiaheng Xie *Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Min Zhang *Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
Min QiDepartment of Burns and Plastic Surgery, Shenzhen Hospital of Southern Medical University, Shenzhen, Guangdong, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Melanoma is a highly aggressive skin cancer that accounts for a disproportionate number of skin cancer-related deaths due to early metastasis and therapy resistance. Programmed cell death (PCD), including ferroptosis and apoptosis, plays a crucial role in tumor progression and therapy response. Among these, triaptosis is a newly described form of PCD. It represents a novel mechanism of cell death with potential implications for cancer treatment. However, its role in melanoma remains largely unexplored. Methods: We explored the role of triaptosis in melanoma by integrating single-cell and bulk RNA sequencing data. Key triaptosis-related genes and pathways were identified and incorporated into machine learning models to construct a prognostic signature. The TCGA-SKCM cohort served as the training dataset, and GEO datasets were used for validation. Results: A robust prognostic model based on triaptosis-associated signature (TAS) was established using the SurvivalSVM algorithm. This model showed superior predictive performance, with consistently high concordance index (C-index) values across independent validation datasets. Kaplan-Meier survival analysis indicated that high-risk patients had significantly worse overall survival than low-risk patients. The model's predictive accuracy was confirmed through receiver operating characteristic (ROC) curve analysis and principal component analysis (PCA). Moreover, immune infiltration and tumor microenvironment (TME) analyses revealed significant associations between TAS and immune cell populations. Conclusion: Triaptosis-related gene expression patterns are closely linked with melanoma prognosis and immune infiltration. Our findings provide novel insights into triaptosis as a potential biomarker and therapeutic target, offering strategies to overcome treatment resistance in melanoma.

Indexed as

cancercell deathmelanomatargettumor microenvironment

Identifiers

PMID40535575
PMCPMC12174916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.